Resverlogix
Late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses.
Launch date
Employees
Market cap
CAD16.6m
Enterprise valuation
CAD29m (Public information from Sep 2024)
Share price
CAD0.07 RVX.TO
Calgary Alberta (HQ)
Financials
Estimates*
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| EBITDA | (32.6m) | (38.9m) | (37.1m) | (74.2m) | (14.9m) | (11.7m) | (5.2m) |
| Profit | (44.6m) | (54.6m) | (157m) | 118m | (24.8m) | (3.6m) | (16.7m) |
| EV / EBITDA | -11.5x | -13.4x | -9.3x | -2.9x | -10.5x | -6.6x | -16.3x |
| R&D budget | 28.9m | 35.4m | 31.1m | 15.8m | 4.5m | 5.5m | 3.2m |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | CAD70.7m | Late VC | |
| N/A | N/A | IPO | |
$25.0m | Post IPO Equity | ||
| N/A | $1.8m | Post IPO Equity | |
| N/A | $1.6m | Post IPO Equity | |
| N/A | $2.3m | Post IPO Equity | |
| N/A | $10.0m | Post IPO Equity | |
| N/A | N/A | Early VC | |
| N/A | CAD21.8m | Post IPO Equity | |
| N/A | $2.0m | Post IPO Equity | |
* |
| $6.0m | Post IPO Convertible |
| Total Funding | CAD70.7m | ||
Related Content
Recent News about Resverlogix
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.